ZTI BIOSCIENCES
Tuesday, February 27, 2024
Uris
Oncology
ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology.
[Business Model]
BM1) Validating TERACARRIER™ technology through FDA Licensing strategy.
BM2) Licensing out to global pharmaceutical companies and expanding pipeline based on the TERACARRIER™ platform.
BM3) Launching a radiopharmaceutical CDMO business based on TERACARRIER™.
[Pipeline]
ZTI-101 utilizes 177Lu for orphan disease (ovarian cancer), targeting IND approval this year. ZTI-201 is using 225Ac, which has strong therapeutic activity, overcoming the technically challenging delivery of high-energy alpha daughters through TERACARRIER™ technology. TERACARRIER™'s versatile platform extends to the new targeting agent applied pipeline, designed for solid tumor treatment using from small molecule to antibody.
Country
Korea, Republic of
Website
http://www.zti-bio.com/
CEO/Top Company Official
Jaden Hyungseok Chang
Lead Product in Development
ZTI-101 (Lu-177 TERACARRIER)
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
3
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}